ProCE Banner Activity

Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer

Slideset Download
Conference Coverage
In these subanalyses of the CALGB/SWOG 80405 trial, tumor sidedness was a prognostic factor independent of other molecular features, and BRAF status was also a strong prognostic marker for patients with mCRC receiving first-line treatment.

Released: June 14, 2017

Expiration: June 13, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology